Skip to content

Advertisement

  • Erratum
  • Open Access

Erratum to: Results of multicenter double-blind placebo-controlled phase II clinical trial of Panagen preparation to evaluate its leukostimulatory activity and formation of the adaptive immune response in patients with stage II-IV breast cancer

  • Anastasia S. Proskurina1,
  • Tatiana S. Gvozdeva2,
  • Ekaterina A. Alyamkina1,
  • Evgenia V. Dolgova1,
  • Konstantin E. Orishchenko1,
  • Valeriy P. Nikolin1,
  • Nelly A. Popova1, 3,
  • Sergey V. Sidorov3, 4,
  • Elena R. Chernykh5,
  • Alexandr A. Ostanin5,
  • Olga Y. Leplina5,
  • Victoria V. Dvornichenko6, 7,
  • Dmitriy M. Ponomarenko6, 7,
  • Galina S. Soldatova3, 8,
  • Nikolay A. Varaksin9,
  • Tatiana G. Ryabicheva9,
  • Peter N. Uchakin10,
  • Stanislav N. Zagrebelniy3,
  • Vladimir A. Rogachev1,
  • Sergey S. Bogachev1Email author and
  • Mikhail A. Shurdov11
Contributed equally
BMC Cancer201616:117

https://doi.org/10.1186/s12885-016-2163-y

Received: 11 February 2016

Accepted: 11 February 2016

Published: 17 February 2016

The original article was published in BMC Cancer 2015 15:122

Erratum

After publication of this work [1], we noted that we inadvertently failed to include the complete list of all co-authors. In this erratum we rectify these mistakes. The full list of authors and the updated Authors Contributions section are reported below. We apologize for any inconvenience this oversight may have caused.

Corrected Authors’ List:

Anastasia S. Proskurina, Tatiana S. Gvozdeva, Ekaterina A. Alyamkina, Evgenia V. Dolgova, Konstantin E. Orishchenko, Valeriy P. Nikolin, Nelly A. Popova, Sergey V. Sidorov, Elena R. Chernykh, Alexandr A. Ostanin, Olga Y. Leplina, Victoria V. Dvornichenko, Dmitriy M. Ponomarenko, Galina S. Soldatova, Nikolay A. Varaksin, Tatiana G. Ryabicheva, Peter N. Uchakin, Stanislav N. Zagrebelniy, Vladimir A. Rogachev, Sergey S. Bogachev, and Mikhail A. Shurdov.

Notes

Declarations

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Institute of Cytology and Genetics, Siberian Branch of the Russian Academy of Sciences, Novosibirsk, Russia
(2)
Novosibirsk State Medical University, Novosibirsk, Russia
(3)
Novosibirsk State University, Novosibirsk, Russia
(4)
Oncology Department of Municipal Hospital No 1, Novosibirsk, Russia
(5)
Institute of Clinical Immunology, Siberian Branch of the Russian Academy of Medical Sciences, Novosibirsk, Russia
(6)
Irkutsk State Medical Academy of Postgraduate Education, Irkutsk, Russia
(7)
Regional Oncology Dispensary, Irkutsk, Russia
(8)
Clinic Department of the Central Clinical Hospital, Siberian Branch of the Russian Academy of Sciences, Novosibirsk, Russia
(9)
CJSC «Vector-best», Koltsovo, Russia
(10)
Mercer University School of Medicine, Macon, USA
(11)
LLC 1 Panagen, Gorno-Altaisk, Russia

References

  1. Proskurina AS, Gvozdeva TS, Alyamkina EA, Dolgova EV, Orishchenko KE, Nikolin VP, et al. Results of multicenter double-blind placebo-controlled phase II clinical trial of Panagen preparation to evaluate its leukostimulatory activity and formation of the adaptive immune response in patients with stage II-IV breast cancer. BMC Cancer. 2015;15:122. doi:10.1186/s12885-015-1142-z.PubMed CentralView ArticlePubMedGoogle Scholar

Copyright

© Proskurina et al. 2016

Advertisement